Why Reata Pharma Shares Are Skyrocketing Today
The FDA approved Reata Pharmaceuticals Inc’s (NASDAQ:RETA) Skyclarys (omaveloxolone) for Friedreich’s ataxia in adults and adolescents aged 16 and older. With…
Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race
Guggenheim Partners initiated coverage on Structure Therapeutics Inc (NASDAQ:GPCR) with a Buy rating and a price target of $50 based on the multi-billion-dollar…
Revolution Medicines’ Early-Data Validation For Cancer Program Wins Price Target Boost By This Analyst
Needham increased the price target for Revolution Medicines Inc (NASDAQ:RVMD) from $32 to $38 with a Buy rating. In its Q4 earnings release, Revolution…
Analysts Remain Bullish On SI-BONE, Forecast Q4’s Strength To Continue In 2023
SI-BONE Inc (NASDAQ:SIBN) reported a Q4 EPS loss of $(0.32), beating the consensus of $(0.40) and sales of $31.95 million,…
Merck Discontinues Two Keytruda Combo Therapy Trials In Prostate & Lung Cancer Settings
Merck & Co Inc (NYSE:MRK) is discontinuing the Phase 3 KEYNOTE-641 trial evaluating Keytruda (pembrolizumab) in combination with enzalutamide and androgen…
AdaptHealth’s Q4 Core Earnings Fall Short Of Expectations, Trims Annual Guidance
AdaptHealth Corp (NASDAQ:AHCO) delivered Q4 revenue of $780.28 million, +11.1% Y/Y, including non-acquired growth of 5.3%, missing the consensus of…
BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023
Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported a break-even in Q4 FY22 compared to a loss of $(0.32) a year ago and the…
Swiss Regulatory Authority Find Credit Suisse In Serious Violation Regarding Greensill Debacle
The Swiss Financial Market Supervisory Authority FINMA has concluded its enforcement proceedings against Credit Suisse Group AG (NYSE:CS) concerning its business relationship…
Analyst Says This Small Cap Biotech Firm Has ‘Very Valuable Therapeutic,’ Upgrades Stock
Raymond James has upgraded Dyne Therapeutics Inc (NASDAQ:DYN) from Outperform to Strong Buy and raised the price target to $27 from $16.…
Dr. Reddy’s Seeks Gaining Foothold In Women’s Health Via Mayne Pharma’s U.S. Generic Prescription Deal
Dr. Reddy’s Laboratories Ltd (NYSE:RDY) has agreed to acquire the U.S. generic prescription product portfolio of Australia-based Mayne Pharma Group Limited (OTC:MAYND) (OTC:MAYNF)…